Stocks-SAGE-Sage Therapeutics Inc

SAGE Sage Therapeutics Inc

24.72 0 (0%)
Market ClosedDelayed Prices By NASDAQ, in USD
Trade
Trade

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2022: Sage Therapeutics Inc's revenues increased by 21.85% and amounted to 7.69M. Net income decreased by 16.36% to -532.78M. Net assets decreased by NaN to 1.25B and EPS decreased from N/A to -8.98.
SAGE's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
78.61%
Net Profit Margin
-6,010.21%
Operating Margin
-5,798.56%
Return On Investment
-27.44%